Does Nystatin Treat Toenail Fungus?

Nystatin does not effectively treat toenail fungus. While nystatin is a well-known antifungal, it targets a narrow range of fungi and cannot penetrate the hard nail plate to reach an infection underneath. The overwhelming majority of toenail fungus cases are caused by organisms that nystatin has no meaningful activity against in the first place, making it a poor match on two separate levels. Proven treatments exist, but they look nothing like nystatin.

What Nystatin Actually Does

Nystatin belongs to the polyene class of antifungals, which work by physically binding to ergosterol, the main sterol in fungal cell membranes. When nystatin latches onto ergosterol, it disrupts the membrane’s structure, causing the cell to leak and die.¹ One reason nystatin is relatively safe for human cells is that our membranes use cholesterol instead of ergosterol, and nystatin binds far less strongly to cholesterol.²

This mechanism makes nystatin effective against yeasts, particularly Candida species. It is commonly used for oral thrush, intestinal Candida overgrowth, and skin-fold yeast infections. But its antifungal reach essentially stops at Candida and a few closely related yeasts. Dermatophytes, the group of fungi responsible for athlete’s foot, ringworm, and the vast majority of toenail infections, are not meaningfully susceptible to nystatin.

Why Toenail Fungus Is Almost Never a Nystatin Problem

Toenail fungus, clinically called onychomycosis, is not one infection caused by one type of organism. But when researchers culture infected toenails, dermatophytes dominate. In a survey of over 2,700 patients, dermatophytes accounted for roughly 82% of toenail infections, while yeasts made up only about 6% and nondermatophyte molds about 4%.³ Other studies consistently confirm that dermatophytes are the primary cause, with trauma as a key risk factor for developing the infection.⁴

So if you walk into a pharmacy looking for something to put on a thick, discolored toenail, nystatin would be targeting the wrong organism in at least eight out of ten cases. Even in the small fraction of toenail infections caused by Candida, nystatin faces a separate and arguably bigger obstacle: it cannot get through the nail.

The Nail Penetration Problem

Your toenail is made of densely packed keratin, and getting a drug through it is genuinely difficult. The nail plate acts as a physical barrier that blocks most topical medications from reaching the nail bed where fungi thrive.⁵ The physicochemical properties of a drug, including its molecular size, its ability to dissolve in the right conditions, and its affinity for keratin, determine whether it can cross this barrier at all.⁶

Nystatin was never designed with nail penetration in mind. It was developed for mucosal surfaces like the mouth and intestinal tract, where it makes direct contact with yeast cells. It is available as oral suspensions, tablets, and creams, none of which are formulated to cross a keratin barrier. Even dedicated nail-specific antifungal formulations, engineered from the ground up to penetrate nails, achieve only modest cure rates. A drug that was never designed for this task and comes in no nail-appropriate delivery system has essentially zero chance of reaching therapeutic levels beneath the toenail.

What About the Rare Candida Toenail Infection

It is worth acknowledging that Candida can sometimes cause toenail infections. This is more common in fingernails than toenails, and it tends to show up in people whose hands are frequently wet or who have compromised immune systems. Still, it does happen in toenails.⁷

Lab testing shows that various Candida species are sensitive to polyenes like nystatin in vitro, and that sensitivity to polyenes sometimes surpasses sensitivity to certain azole drugs like fluconazole.⁸ That might seem encouraging, but “works in a lab dish” and “works inside a toenail” are different things entirely. The nail penetration barrier remains. Even if you confirmed that your toenail infection was caused by Candida, a dermatologist would prescribe an antifungal that can actually reach the infection site, not nystatin.

Nystatin is used topically for yeast infections in skin folds, where there is no keratin barrier in the way.¹ It works well for that purpose. The problem is not that nystatin is a bad drug; it is simply the wrong tool for the specific environment of the toenail.

Treatments That Actually Work for Toenail Fungus

Treating toenail fungus successfully usually requires either an oral antifungal or one of the newer topical agents specifically designed for nails, and often both take months of use. Cure rates are lower than you might expect, even with the best available options, because the nail grows slowly and the fungus is tenacious.

Oral Antifungals

Terbinafine taken by mouth is the most widely used first-line treatment for dermatophyte toenail infections. It is fungicidal, meaning it kills the fungus rather than merely slowing its growth, and it achieves high concentrations in the nail relative to what is needed to eliminate the organism.⁹ In a head-to-head trial of 12 weeks of continuous therapy, about 73% of patients on terbinafine had negative mycology (no detectable fungus) by week 48, compared to roughly 46% on itraconazole. Clinical improvement followed a similar pattern.¹⁰

Itraconazole, an azole antifungal, is the typical alternative when terbinafine is not suitable. It is primarily fungistatic rather than fungicidal, which may explain its somewhat higher relapse rates over the long term.⁹ Both drugs require liver function monitoring and carry a small risk of side effects, which is one reason doctors do not prescribe them casually.

Topical Nail-Specific Agents

For mild to moderate cases, or when oral drugs are not an option, topical agents formulated to penetrate the nail represent a reasonable alternative. Efinaconazole 10% topical solution, applied daily for 48 weeks, achieved complete cure rates of about 15-18% in two large trials, with mycological cure rates in the mid-50s percent.¹¹ Those numbers might seem low, but they were clearly superior to placebo and the drug was well tolerated.

Tavaborole 5% solution, another nail-specific topical, works through a different mechanism. In two phase III trials, completely or almost clear nails combined with negative lab results were achieved in about 15-18% of patients, again significantly better than vehicle alone.¹² Both efinaconazole and tavaborole were developed specifically to overcome the nail plate barrier, something nystatin formulations were never engineered to do.¹³

Ciclopirox 8% nail lacquer, an older topical option, has been available for longer but produced underwhelming results even when combined with regular nail debridement.¹³ It remains available but has largely been eclipsed by the newer formulations.

Why Getting the Right Diagnosis Matters

A thick, yellow, crumbly toenail is not always fungal. Psoriasis, lichen planus, chronic trauma, and simple aging can all produce nail changes that mimic onychomycosis. Roughly half of abnormal-looking nails referred for evaluation turn out to not have a fungal infection at all. Treating a non-fungal nail problem with an antifungal, nystatin or otherwise, is a waste of time and money.

Traditional diagnostic methods include scraping the nail and examining it under a microscope with potassium hydroxide preparation, sending a sample for fungal culture, and sometimes examining a nail clipping with histopathology.¹⁴ Newer molecular tests, including PCR-based assays, can identify specific fungal species directly from a nail sample, which helps guide treatment choices.¹⁵

Knowing the exact organism matters. A dermatophyte infection calls for terbinafine or an azole. A Candida infection might respond better to itraconazole or fluconazole. A nondermatophyte mold may need a different approach altogether. Even in the rare Candida nail case, a targeted systemic or nail-penetrating azole is the standard of care, not nystatin.

The Role of Debridement

Whether you use a topical or systemic antifungal, physically removing as much diseased nail as possible through debridement helps the drug reach the remaining infection more easily. A randomized trial comparing debridement alone to debridement combined with a topical antifungal nail lacquer found that the combination group achieved mycological cure in about 77% of patients over a median follow-up of around 10 months, while debridement alone produced zero mycological cures.¹⁶

Debridement on its own does not cure the infection, but it meaningfully boosts the effectiveness of whatever antifungal is being used. Podiatrists and dermatologists often thin the nail or trim away visibly infected portions before starting topical therapy. If you are self-treating with an over-the-counter product, gently filing the nail surface can improve penetration, though aggressive self-debridement is best left to professionals.

Toenail Fungus in People With Diabetes

Onychomycosis disproportionately affects people with diabetes, and the consequences can be more serious than cosmetic embarrassment. Fungal nail infections in diabetic feet tend to be more severe and carry a higher risk of complications like secondary bacterial infections and ulceration.¹⁷ Because diabetes impairs blood flow and immune function in the feet, even a seemingly minor toenail infection can become a pathway to more dangerous problems.

Reducing the burden of superficial fungal infections like onychomycosis and athlete’s foot in diabetic patients may help prevent diabetic foot ulcers and the infections that follow them.¹⁸ This population has an even stronger reason to get proper treatment rather than reach for an ineffective option like nystatin. At the same time, oral antifungals require careful consideration in diabetic patients because of potential drug interactions and the need for liver monitoring. Topical nail-specific agents can be an attractive alternative in this group precisely because they minimize systemic exposure.

Why This Misconception Persists

Nystatin has been around since the 1950s and is one of the most familiar antifungal names to the general public. People who have used nystatin cream for a yeast rash or nystatin oral suspension for thrush naturally assume it should work for any fungal infection. The logic feels sound: fungus is fungus, so an antifungal should handle it. But fungi are a sprawling kingdom of organisms, and no single antifungal covers them all. Nystatin’s activity against Candida says nothing about its ability to affect dermatophytes, which are about as genetically different from Candida as a cat is from a fish within the animal kingdom.

Over-the-counter antifungal creams marketed for athlete’s foot often contain clotrimazole, miconazole, or terbinafine, all of which have activity against dermatophytes. Some people try these on their toenails as well, and while they are at least targeting the right organisms, the nail penetration issue remains. The cream sits on top of the hard nail and never reaches the infection below. This is the same fundamental problem nystatin would face, except nystatin would also be aimed at the wrong organism.

Home remedies and alternative treatments, from tea tree oil to Vicks VapoRub, fill internet forums. Some have limited in-vitro antifungal activity, but none have the kind of clinical trial evidence that efinaconazole, tavaborole, or oral terbinafine do. If you want to resolve toenail fungus rather than watch it slowly consume the entire nail, evidence-based prescription treatment is the path with the best odds. Nystatin, for all its usefulness in the right context, is simply not part of that path.

1
PubMed Central. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
2
PubMed. Direct observation of nystatin binding to the plasma membrane of living cells
3
JAMA Dermatology. Factors Influencing Coexistence of Toenail Onychomycosis With Tinea Pedis and Other Dermatomycoses: A Survey of 2761 Patients
4
International Journal of Pharmacy and Pharmaceutical Sciences. Onychomycosis: Unraveling the Role of Dermatophytes in Nail Infections
5
PubMed. Insights into drug delivery across the nail plate barrier
6
PubMed Central. Assessment of the nail penetration of antifungal agents, with different physico-chemical properties
7
PubMed Central. Onychomycosis: pathogenesis, diagnosis, and management
8
PubMed Central. Candida Parapsilosis and Candida Guillermondii: Emerging Pathogens in Nail Candidiasis
9
JAMA Dermatology. Long-term Effectiveness of Treatment With Terbinafine vs Itraconazole in Onychomycosis: A 5-Year Blinded Prospective Follow-up Study
10
PubMed. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day
11
PubMed. Efinaconazole 10% topical solution for the topical treatment of onychomycosis of the toenail
12
PubMed. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies
13
PubMed Central. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents
14
PubMed Central. Diagnosis of Onychomycosis: From Conventional Techniques and Dermoscopy to Artificial Intelligence
15
Medical Mycology. Clinical evaluation of the DermaGenius® Nail real-time PCR assay for the detection of dermatophytes and Candida albicans in nails
16
PubMed. Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial
17
PubMed. Treating onychomycosis in diabetic patients: risk, therapy, and topical opportunity
18
PubMed Central. Diabetic Foot and Fungal Infections: Etiology and Management from a Dermatologic Perspective